

Appendix 3Y – Late Lodgement Notice

Please find attached an Appendix 3Y - Change of Director's Interest Notice ("**Appendix 3Y**") for Dr Neil Gunn, Director of Genetic Signatures Limited (ASX: GSS) ("**GSS**" or the "**Company**").

The Appendix 3Y for Dr Gunn includes the issue of 500,000 options, approved by shareholders at the Company's 2024 Annual General Meeting on 20 November 2024, and notified in the Appendix 3G – Notification regarding unquoted securities released to the market on 9 December 2024.

In relation to the late lodgement of the attached Appendix 3Y, we advise as follows:

1. The Appendix 3Y is being lodged late due to an administrative oversight. As soon as the oversight was identified, the document was prepared and promptly lodged with the ASX.
2. The Company is satisfied that it has the necessary reporting and notification practices in place to ensure compliance with its disclosure requirements under ASX Listing Rules 3.19A and 3.19B.
3. The Company considers that the late lodgement is an isolated incident and believes that its current practices are adequate to ensure compliance with the ASX Listing Rules.

– END –

Announcement authorised for release by the Company Secretary of Genetic Signatures Limited.

For further information, see our website (www.geneticsignatures.com) or contact us:

Karl Pechmann

Chief Financial Officer and Company Secretary

karl.pechmann@geneticsignatures.com

T: +61 (0)2 9870 7580

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	GENETIC SIGNATURES LIMITED
ABN	30 095 913 205

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Neil Gunn
Date of last notice	22 November 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	6 December 2024
No. of securities held prior to change	250,000 options
Class	Options
Number acquired	500,000 options exercisable at \$0.69 (69 cents), expiring 6 December 2039
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A (see below)

+ See chapter 19 for defined terms.

No. of securities held after change	750,000 options
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of 500,000 options pursuant to Resolution 9 as approved at the Company's 2024 Annual General Meeting on 20 November 2024.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <input type="checkbox"/> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.